Total Payments
$269,972
2024 Payments
$23,208
Companies
40
Transactions
230
Medicare Patients
29,691
Medicare Billing
$4.7M
Payment Breakdown by Category
Research$261,013 (96.7%)
Other$5,000 (1.9%)
Food & Beverage$3,562 (1.3%)
Education$292.47 (0.1%)
Consulting$104.95 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $261,013 | 21 | 96.7% |
| Charitable Contribution | $5,000 | 1 | 1.9% |
| Food and Beverage | $3,562 | 202 | 1.3% |
| Education | $292.47 | 5 | 0.1% |
| Consulting Fee | $104.95 | 1 | 0.0% |
Payments by Type
Research
$261,013
21 transactions
General
$8,959
209 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Eli Lilly and Company | $261,013 | 21 | $0 (2024) |
| SRS Medical Systems, Inc. | $5,000 | 1 | $0 (2020) |
| Astellas Pharma US Inc | $779.87 | 41 | $0 (2024) |
| Janssen Biotech, Inc. | $594.67 | 34 | $0 (2024) |
| Endo Pharmaceuticals Inc. | $234.81 | 15 | $0 (2022) |
| NeoTract Inc. | $218.46 | 5 | $0 (2017) |
| NxThera, Inc. | $203.86 | 2 | $0 (2017) |
| Bayer Healthcare Pharmaceuticals Inc. | $191.32 | 11 | $0 (2024) |
| Amgen Inc. | $186.22 | 10 | $0 (2023) |
| ABBVIE INC. | $154.12 | 10 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $23,208 | 22 | Eli Lilly and Company ($22,890) |
| 2023 | $69,979 | 23 | Eli Lilly and Company ($69,660) |
| 2022 | $42,264 | 30 | Eli Lilly and Company ($41,805) |
| 2021 | $15,987 | 29 | Eli Lilly and Company ($15,620) |
| 2020 | $10,412 | 21 | Eli Lilly and Company ($5,075) |
| 2019 | $34,621 | 25 | Eli Lilly and Company ($34,200) |
| 2018 | $54,045 | 24 | Eli Lilly and Company ($53,713) |
| 2017 | $19,457 | 56 | Eli Lilly and Company ($18,050) |
All Payment Transactions
230 individual payment records from CMS Open Payments — Page 1 of 10
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/17/2024 | ABBVIE INC. | BOTOX (Biological) | Food and Beverage | In-kind items and services | $14.33 | General |
| Category: BOTOX THERAPEUTIC | ||||||
| 12/10/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $14.82 | General |
| Category: ONCOLOGY | ||||||
| 11/20/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $22.46 | General |
| Category: ONCOLOGY | ||||||
| 11/19/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $15.52 | General |
| Category: HORMONE THERAPY | ||||||
| 11/06/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $13.28 | General |
| Category: ONCOLOGY | ||||||
| 10/28/2024 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $13.39 | General |
| Category: Oncology | ||||||
| 10/15/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $14.59 | General |
| Category: Oncology | ||||||
| 09/25/2024 | Verity Pharmaceuticals Inc. | Trelstar (Drug) | Food and Beverage | Cash or cash equivalent | $16.49 | General |
| Category: Prostate cancer | ||||||
| 09/18/2024 | BIOPROTECT MEDICAL, INC. | BIOPROTECT BALLOON IMPLANT SYSTEM (Device) | Food and Beverage | In-kind items and services | $14.35 | General |
| Category: Rectal Spacers Used in Prostate Cancer Radiation Therapy | ||||||
| 09/11/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $18.13 | General |
| Category: ONCOLOGY | ||||||
| 08/22/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $22.69 | General |
| Category: ONCOLOGY | ||||||
| 08/15/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $21.01 | General |
| Category: ONCOLOGY | ||||||
| 07/09/2024 | Janssen Biotech, Inc. | ERLEADA (Drug) | Food and Beverage | In-kind items and services | $15.83 | General |
| Category: Oncology | ||||||
| 06/17/2024 | 180 Medical, Inc. | — | Food and Beverage | In-kind items and services | $14.48 | General |
| 06/05/2024 | Sumitomo Pharma America, Inc. | ORGOVYX (Drug) | Food and Beverage | In-kind items and services | $19.09 | General |
| Category: HORMONE THERAPY | ||||||
| 05/15/2024 | Tolmar, Inc. | ELIGARD (Drug) | Food and Beverage | Cash or cash equivalent | $20.67 | General |
| Category: ONCOLOGY | ||||||
| 04/18/2024 | Ferring Pharmaceuticals Inc. | ADSTILADRIN (Biological) | Food and Beverage | In-kind items and services | $15.45 | General |
| Category: ONCOLOGY | ||||||
| 03/26/2024 | Sumitomo Pharma America, Inc. | GEMTESA (Drug) | Food and Beverage | In-kind items and services | $17.58 | General |
| Category: UROLOGY | ||||||
| 03/07/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $225.00 | Research |
| Study: A PHASE 2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | ||||||
| 02/21/2024 | Astellas Pharma US Inc | Xtandi (Drug) | Food and Beverage | In-kind items and services | $13.60 | General |
| Category: Oncology | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $15,930.00 | Research |
| Study: A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | ||||||
| 01/04/2024 | Eli Lilly and Company | — | — | Cash or cash equivalent | $6,735.00 | Research |
| Study: A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | ||||||
| 11/30/2023 | Verity Pharmaceuticals Inc. | Trelstar (Drug) | Food and Beverage | Cash or cash equivalent | $16.69 | General |
| Category: Prostate cancer | ||||||
| 10/26/2023 | Bayer Healthcare Pharmaceuticals Inc. | Nubeqa (Drug), Xofigo | Food and Beverage | In-kind items and services | $14.25 | General |
| Category: Oncology | ||||||
| 10/19/2023 | Verity Pharmaceuticals Inc. | Trelstar (Drug) | Food and Beverage | Cash or cash equivalent | $17.20 | General |
| Category: Prostate cancer | ||||||
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| A MULTICENTER, RANDOMIZED, DOUBLE-BLIND STUDY OF ERLOTINIB IN COMBINATION WITH RAMUCIRUMAB OR PLACEBO IN PREVIOUSLY UNTREATED PATIENTS WITH EGFR MUTATION-POSITIVE METASTATIC NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $104,213 | 3 |
| A MULTICENTER, RANDOMIZED, OPEN LABEL, PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE, ADVANCED, KINASE INHIBITOR NAIVE, RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $50,610 | 4 |
| A MULTICENTER RANDOMIZED OPEN LABEL PHASE 3 TRIAL COMPARING SELPERCATINIB TO PHYSICIANS CHOICE OF CABOZANTINIB OR VANDETANIB IN PATIENTS WITH PROGRESSIVE ADVANCED KINASE INHIBITOR NAIVE RET MUTANT MEDULLARY THYROID CANCER (LIBRETTO 531) | Eli Lilly and Company | $30,660 | 1 |
| A STUDY OF SELPERCATINIB (LY3527723) IN PARTICIPANTS WITH ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER (LIBRETTO-431) | Eli Lilly and Company | $24,930 | 2 |
| LIBRETTO-431: A MULTICENTER, RANDOMIZED, OPEN-LABEL, PHASE 3 TRIAL COMPARING LOXO-292 TO PLATINUM-BASED AND PEMETREXED THERAPY WITH OR WITHOUT PEMBROLIZUMAB AS INITIAL TREATMENT OF ADVANCED OR METASTATIC RET FUSION-POSITIVE NON-SMALL CELL LUNG CANCER | Eli Lilly and Company | $20,965 | 3 |
| A PHASE 2 STUDY OF ORAL LOXO-305 IN PATIENTS WITH PREVIOUSLY TREATED CHRONIC LYMPHOCYTIC LEUKEMIA/SMALL LYMPHOCYTIC LYMPHOMA (CLL/SLL) OR NON-HODGKIN LYMPHOMA (NHL) | Eli Lilly and Company | $10,680 | 3 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $10,575 | 1 |
| A PHASE 2 STUDY OF ORAL SELPERCATINIB (LOXO-292) IN PATIENTS WITH ADVANCED SOLID TUMORS, INCLUDING REARRANGED IN TRANSFECTION (RET) FUSION-POSITIVE SOLID TUMORS, MEDULLARY THYROID CANCER AND OTHER TUMORS WITH RET ACTIVATION | Eli Lilly and Company | $6,630 | 3 |
| A RANDOMIZED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE 3 STUDY OF CAPECITABINE AND CISPLATIN WITH OR WITHOUT RAMUCIRUMAB AS FIRST-LINE THERAPY IN PATIENTS WITH METASTATIC GASTRIC OR GASTROESOPHAGEAL JUNCTION ADENOCARCINOMA-RAINFALL | Eli Lilly and Company | $1,750 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 45 | 7,229 | 64,540 | $5.8M | $1.0M |
| 2022 | 59 | 8,369 | 73,491 | $7.3M | $1.4M |
| 2021 | 56 | 7,886 | 78,936 | $7.1M | $1.4M |
| 2020 | 49 | 6,207 | 66,654 | $5.1M | $905,814 |
Total Patients
29,691
Total Services
283,621
Medicare Billing
$4.7M
Procedure Codes
209
All Medicare Procedures & Services
209 procedure records from CMS Medicare Utilization — Page 1 of 9
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 972 | 2,200 | $330,000 | $169,832 | 51.5% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 617 | 1,159 | $260,775 | $128,152 | 49.1% |
| 88120 | Cell examination of urine, manual | Office | 2023 | 138 | 419 | $628,500 | $116,070 | 18.5% |
| 52224 | Destruction of growth of bladder and urethra using an endoscope, less than 0.5 cm | Office | 2023 | 51 | 71 | $497,000 | $53,400 | 10.7% |
| J0897 | Injection, denosumab, 1 mg | Office | 2023 | 13 | 2,520 | $84,000 | $46,938 | 55.9% |
| 88313 | Special stained specimen slides to examine tissue including interpretation and report | Office | 2023 | 372 | 1,159 | $185,600 | $44,756 | 24.1% |
| 88112 | Cell examination of specimen, selective cellular enhancement technique | Office | 2023 | 372 | 1,169 | $204,750 | $35,270 | 17.2% |
| 51792 | Assessment of muscle signal of pelvic nerves | Office | 2023 | 134 | 134 | $134,000 | $34,612 | 25.8% |
| 76770 | Complete ultrasound scan behind abdominal cavity | Office | 2023 | 313 | 367 | $275,250 | $34,304 | 12.5% |
| J9217 | Leuprolide acetate (for depot suspension), 7.5 mg | Office | 2023 | 30 | 261 | $195,750 | $33,420 | 17.1% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 226 | 226 | $67,800 | $32,166 | 47.4% |
| 52648 | Complete laser vaporization of prostate including control of bleeding using an endoscope | Office | 2023 | 19 | 19 | $228,000 | $27,589 | 12.1% |
| 51728 | Complex measurement of pressure of urine flow in bladder with voiding pressure studies | Office | 2023 | 69 | 74 | $333,760 | $25,824 | 7.7% |
| 76872 | Ultrasound scan of pelvic region through rectum | Office | 2023 | 175 | 192 | $134,400 | $23,796 | 17.7% |
| 52281 | Dilation of urethra using an endoscope | Office | 2023 | 57 | 70 | $210,000 | $22,221 | 10.6% |
| 51798 | Ultrasound measurement of bladder capacity after voiding | Office | 2023 | 1,007 | 2,146 | $203,965 | $20,676 | 10.1% |
| 52000 | Diagnostic exam of bladder and urethra using an endoscope | Office | 2023 | 84 | 88 | $105,600 | $20,360 | 19.3% |
| 91122 | Study of rectum sensitivity and function | Office | 2023 | 22 | 73 | $109,500 | $18,873 | 17.2% |
| 51784 | Non-needle measurement and recording of electrical activity of muscles at bladder and bowel openings | Office | 2023 | 263 | 348 | $417,600 | $17,818 | 4.3% |
| 52214 | Destruction of tissue of bladder, urethra, or surrounding glands using an endoscope | Office | 2023 | 23 | 24 | $168,000 | $17,553 | 10.4% |
| 51797 | Insertion of device into abdomen with pressure and urine flow rate study | Office | 2023 | 77 | 83 | $82,915 | $15,172 | 18.3% |
| G0416 | Surgical pathology, gross and microscopic examinations, for prostate needle biopsy, any method | Office | 2023 | 32 | 64 | $115,200 | $10,660 | 9.3% |
| 51725 | Simple measurement of pressure of urine flow in bladder | Office | 2023 | 32 | 43 | $107,500 | $9,205 | 8.6% |
| 55700 | Biopsy of prostate gland | Office | 2023 | 35 | 35 | $52,500 | $7,828 | 14.9% |
| 51702 | Simple insertion of temporary bladder tube | Office | 2023 | 34 | 125 | $93,750 | $7,109 | 7.6% |
About Dr. Joel Sherman, M.D
Dr. Joel Sherman, M.D is a Specialist healthcare provider based in Staten Island, New York. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/04/2006. The National Provider Identifier (NPI) number assigned to this provider is 1760460430.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Joel Sherman, M.D has received a total of $269,972 in payments from pharmaceutical and medical device companies, with $23,208 received in 2024. These payments were reported across 230 transactions from 40 companies. The most common payment nature is "" ($261,013).
As a Medicare-enrolled provider, Sherman has provided services to 29,691 Medicare beneficiaries, totaling 283,621 services with total Medicare billing of $4.7M. Data is available for 4 years (2020–2023), covering 209 distinct procedure/service records.
Ad
Practice Information
- Specialty Specialist
- Location Staten Island, NY
- Active Since 01/04/2006
- Last Updated 06/25/2024
- Taxonomy Code 174400000X
- Entity Type Individual
- NPI Number 1760460430
Products in Payments
- CYRAMZA (Drug) $105,963
- ERLEADA (Drug) $303.12
- ZYTIGA (Drug) $281.92
- XTANDI (Drug) $280.69
- Urolift - UL400 (Device) $218.46
- Rezum (Device) $203.86
- BOTOX (Biological) $190.58
- Xtandi (Drug) $171.62
- Myrbetriq (Drug) $158.12
- ELIGARD (Drug) $147.23
- AVEED (Biological) $144.20
- GEMTESA (Drug) $137.19
- Xofigo (Drug) $134.85
- XGEVA (Biological) $120.54
- MYRBETRIQ (Drug) $119.60
- Erleada (Drug) $104.04
- KEYTRUDA (Biological) $98.44
- ORGOVYX (Drug) $95.18
- FIRMAGON (Drug) $78.71
- XIAFLEX (Biological) $75.69
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Specialist Doctors in Staten Island
Dr. Joseph D'amore, M.d, M.D
Specialist — Payments: $15,677
Specialist $15,677
Dr. Radha Syed, Md, MD
Specialist — Payments: $15,394
Specialist $15,394
Dr. Corneliu Vulpe, M.d, M.D
Specialist — Payments: $8,683
Specialist $8,683
Dr. John Kung, M.d, M.D
Specialist — Payments: $8,533
Specialist $8,533
Dr. Alexander Sokol, M.d, M.D
Specialist — Payments: $6,219
Specialist $6,219
Dr. Marc Plawker, M.d, M.D
Specialist — Payments: $6,002
Specialist $6,002